Michael Bookman
9PUBLICATIONS
85CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (9)
Sort by Publication Date:
|Oct 03, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.Jung-Min Lee, Mark F Brady, Austin Miller
|May 22, 2024
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.Charles N Landen, Ronald J Buckanovich, Michael W Sill
|Jan 03, 2023
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.Charles N Landen, Luciana Molinero, Habib Hamidi
|Oct 17, 2022
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.Benoit You, Christopher Purdy, Larry J Copeland
|Jul 22, 2022
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.Benoit You, Vasudha Sehgal, Balakrishna Hosmane
|Mar 15, 2022
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.Joyce F Liu, Mark F Brady, Ursula A Matulonis
Pageof 2
Frequent Collaborators
5 joint publications
Kathleen N Moore
3 joint publications
Austin Miller
2 joint publications
Angeles Alvarez Secord
2 joint publications
David Mutch
2 joint publications
Benoit You
2 joint publications
Joan L Walker
2 joint publications
Robert L Coleman
2 joint publications
Gini Fleming
2 joint publications
Mark F Brady
2 joint publications
Joyce F Liu
